Cancer Clinical Trial -Fate Therapeutics-FT536-101

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Drug

FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab

Phase

Phase I

Condition

Non-Small Cell Lung, Colorectal, Breast, Ovarian, Pancreatic, Head and Neck, Gastroesophageal

Keywords

Interleukin-2, Immune Checkpoint Inhibitors